Summit Therapeutics Presents Additional Data From Phase 1b Modified Diet Clinical Trial of SMT C1100 in DMD Patients at WMS
September 30, 2015 07:00 ET
|
Summit Therapeutics plc
10 of 12 Patients Achieved Plasma Concentrations Expected to Increase Utrophin Levels by Approximately 30% or Greater
Phase 2 Proof of Concept Trial Design Outlined, Expected to Initiate Q4...
Summit Therapeutics Reports Financial Results for the Second Quarter Ended 31 July 2015 and Operational Progress
August 27, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 27, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (NASDAQ:SMMT) (AIM:SUMM), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics to Report Second Quarter 2015 Financial Results on 27 August 2015
August 24, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, Aug. 24, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Summit Therapeutics Announces Phase 1b Modified Diet Clinical Trial Achieves Primary Objective in Duchenne Muscular Dystrophy
August 17, 2015 07:00 ET
|
Summit Therapeutics plc
Primary Objective Met; Plasma Absorption of SMT C1100 Observed at a Level Suitable for Further Development
SMT C1100 to Progress into Phase 2 Open-label Trial
Conference Call Scheduled...
Summit Therapeutics Reports First Quarter Results for the Three Months Ended 30 April 2015
June 11, 2015 07:00 ET
|
Summit Therapeutics plc
OXFORD, United Kingdom, June 11, 2015 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (Nasdaq:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular...
Prosensa announces Lancet Neurology publication of an exploratory phase II study (DEMAND II) demonstrating efficacy and safety of drisapersen in patients with Duchenne muscular dystrophy
September 08, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, Sept. 8, 2014 (GLOBE NEWSWIRE) -- LEIDEN, The Netherlands - September 8,
2014 - Prosensa Holding N.V. (NASDAQ: RNA), the
biopharmaceutical company focusing on RNA-modulating...
Prosensa Awarded $200,000 Research Grant from PPMD
June 27, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 27, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Completes Enrollment in Natural History Study of Duchenne Muscular Dystrophy
June 25, 2014 08:00 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, June 25, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA), the Dutch biopharmaceutical
company focusing on RNA-modulating therapeutics for rare diseases
with high...
Prosensa Holding N.V. to Webcast Conference Call Discussing 1st Quarter 2014 Financial Results and Corporate Update on May 20, 2014
May 13, 2014 08:57 ET
|
Prosensa Holding N.V.
Leiden, The Netherlands, May 13, 2014 (GLOBE NEWSWIRE) -- Prosensa Holding N.V. (NASDAQ: RNA) today announced that the
Company will host a conference call and live audio webcast on
Tuesday, May 20,...